Today, more than half of the global disease burden is due to chronic diseases. This is even more so in Asia. Let's see the journey of a patient suffering from some form of chronic disease. The patient goes & visits a clinic where the doctor prescribes a medication & the patient continues on the dosage. The patient only spends up to 5 hours (or <1% of the time) with the doctor in a year. 99% of the time the patient is in the real world, alone & frustrated with their chronic disease. Everyone today has a smartphone & the best, fastest and most inexpensive way to reach the masses is using mobile app. 

However there are many such apps, but only one in Asia which has clinical validation for Type 2 diabetes on an Asian patient population. This is GlycoLeap - a smart coach for patients to monitor their diabetes. It’s a lifestyle change program & complements the effects of medication. We developed GlycoLeap 4 years ago & it’s had over 10,000 patients on the program in Asia. In GlycoLe...
Today, more than half of the global disease burden is due to chronic diseases. This is even more so in Asia. Let's see the journey of a patient suffering from some form of chronic disease. The patient goes & visits a clinic where the doctor prescribes a medication & the patient continues on the dosage. The patient only spends up to 5 hours (or <1% of the time) with the doctor in a year. 99% of the time the patient is in the real world, alone & frustrated with their chronic disease. Everyone today has a smartphone & the best, fastest and most inexpensive way to reach the masses is using mobile app. 

However there are many such apps, but only one in Asia which has clinical validation for Type 2 diabetes on an Asian patient population. This is GlycoLeap - a smart coach for patients to monitor their diabetes. It’s a lifestyle change program & complements the effects of medication. We developed GlycoLeap 4 years ago & it’s had over 10,000 patients on the program in Asia. In GlycoLeap each patient is paired with an actual human coach, not a chatbot. We have rolled this our with AIA & it’s scalable & cost effective.

GlycoLeap’s clinicsl validation published in JMIR: mhealth.jmir.org/2019/5/e12965/

Whats the value in it for Merck?
Merck has a strong General Medicine & Endocrinology portfolio with GLUCOPHAGE (Diabetes), CONCOR (Hypertension) & EUTHYROX (Thyroid). These branded drugs compete with generics in Asia, face pricing pressure and there is very little differentiation. 

GlycoLeap has independently shown to reduce A1c by 1.3 points. 

We’re proposing that Glucophage be paired with GlycoLeap & both be prescribed as a joint therapy. (i.e. Rx + DTx)

This way:
-Merck can move from a product -> product + solutions company
-Merck can go “Beyond the pill” & generate new revenue streams from the joint offering
-Merck will gain access to patients Real World Data
-Better brand recall for Merck medication
Currently GlycoLeap is available in 5 Asian languages & has had over 10,000 patients on the program.
More information

Employees

Rishi Tandon
Admin
Rishi Tandon Sales Director of Business Development